Eck, R. J.
van de Leur, J. J. C. M.
Wiersema, R.
Cox, E. G. M.
Bult, W.
Spanjersberg, A. J.
van der Horst, I. C. C.
Lukens, M. V.
Gans, R. O. B.
Meijer, K.
Keus, F.
Article History
Received: 8 April 2022
Accepted: 28 September 2022
First Online: 18 October 2022
Competing interests
: KM reports consulting fees for discussion of gene therapy study results in hemophilia B (fees paid to institution); Speaker fees for presentations on haemophilia treatment and DOAC antidotes (fees paid to institution); Steering committee for trial of factor VIII concentrate for hemophilia for Bayer, DSMB for trial of PCC for Octapharma (fees paid to institution). The other authors have disclosed no potential conflicts of interest.